These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23377338)

  • 1. Intravenous immunoglobulin-induced hemolytic anemia in a patient with juvenile dermatomyositis.
    Clemenz MR; McGowan Iv JW; Shuler MJ; Lynn AW
    J Drugs Dermatol; 2013 Jan; 12(1):111-3. PubMed ID: 23377338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute hemolysis secondary to high-dose intravenous immunoglobulin in a patient with Stevens-Johnson syndrome.
    Shakouri AA; Bahna SL
    Ann Allergy Asthma Immunol; 2012 Jun; 108(6):463-4. PubMed ID: 22626604
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravenous immunoglobulin-induced hemolytic anemia after thoracoscopic thymectomy for myasthenia gravis.
    Tsukada H; Sunkara R; Chi DD; Keogh D; Gaissert H
    Ann Thorac Surg; 2014 Jun; 97(6):2175-7. PubMed ID: 24882299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-D immunoglobulin-induced prolonged intravascular hemolysis and neutropenia.
    Alioglu B; Avci Z; Ozyurek E; Ozbek N
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):636-9. PubMed ID: 17805040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders.
    Markvardsen LH; Christiansen I; Harbo T; Jakobsen J
    Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].
    Breems DA; de Haas PW; Visscher F; Sabbe LJ; Busch HF; van Doorn PA
    Ned Tijdschr Geneeskd; 1993 Sep; 137(39):1979-82. PubMed ID: 8413708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Don't neglect the rare adverse event with intravenous immunoglobulin: Hemolytic anemia.
    Ucar İ; Koyuncu MB; Solmaz AA; Ugurludogan AC; Mercan S; Kucuk M; Unal T; Mazman S; Atilla E
    Transfus Clin Biol; 2023 Feb; 30(1):11-15. PubMed ID: 36028153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease.
    Nolan BE; Wang Y; Pary PP; Luban NLC; Wong ECC; Ronis T
    Transfusion; 2018 Nov; 58(11):2564-2571. PubMed ID: 30265742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemolytic anemia associated with intravenous immunoglobulin in Kawasaki disease.
    Cheon EJ; Oh JS
    BMC Pediatr; 2024 Jan; 24(1):69. PubMed ID: 38245705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin.
    Peake MF; Perkins P; Elston DM; Older SA; Vinson RP
    Cutis; 1998 Aug; 62(2):89-93. PubMed ID: 9714905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous Immunoglobulin-Associated Hemolytic Anemia.
    Jacobs J; Kneib J; Gabbard A
    Lab Med; 2020 Sep; 51(5):e47-e50. PubMed ID: 32339244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic anemia associated with intravenous immunoglobulin.
    Wilson JR; Bhoopalam H; Fisher M
    Muscle Nerve; 1997 Sep; 20(9):1142-5. PubMed ID: 9270670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
    Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
    Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravenous immunoglobulin administration on erythrocyte and leucocyte parameters.
    Cicha A; Fischer MB; Wesinger A; Haas S; Bauer WM; Wolf HM; Sauerwein KMT; Reininger B; Petzelbauer P; Pehamberger H; Handisurya A
    J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):1004-1010. PubMed ID: 29114967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IVIg and hemolytic anemia risk: dump the anti-A/B already!
    Yazdanbakhsh K; Zhong H
    Transfusion; 2020 Jul; 60(7):1337-1339. PubMed ID: 32681818
    [No Abstract]   [Full Text] [Related]  

  • 16. Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome.
    Chamouni P; Tamion F; Gueit I; Girault C; Lenain P; Varin R; Czernichow P
    Transfus Apher Sci; 2003 Apr; 28(2):117-24. PubMed ID: 12679114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycoplasma pneumoniae infection associated with hemolytic anemia--report of one case.
    Wang JL; Ho MY; Shen EY
    Acta Paediatr Taiwan; 2004; 45(5):293-5. PubMed ID: 15868814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe Hemolytic Anemia Following Intravenous Immunoglobulin in an Infant With Kawasaki Disease.
    Tocan V; Inaba A; Kurano T; Sonoda M; Soebijanto K; Nakayama H
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):e100-e102. PubMed ID: 27879540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.
    Al-Mayouf SM; Laxer RM; Schneider R; Silverman ED; Feldman BM
    J Rheumatol; 2000 Oct; 27(10):2498-503. PubMed ID: 11036850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin therapy in juvenile dermatomyositis.
    Tsai MJ; Lai CC; Lin SC; Chiang BL; Chou CC; Hsieh KH
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1997; 38(2):111-5. PubMed ID: 9151463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.